CERO THERAPEUTICS HOLDINGS, INC. (CERO) Form 10-Q — May 15, 2026
Cero Therapeutics Holdings reported a net loss of $5.9 million for the three months ended March 31, 2026, driven by $4.8 million in operating expenses and $896,722 in derivative expenses related to new convertible debt. The company holds only $857,489 in cash and equivalents against a working capital deficit of approximately $9.8 million and an accumulated deficit of $96.7 million. The filing includes explicit going-concern language, stating that these conditions raise substantial doubt about the company’s ability to continue as a going concern within one year from the date of issuance.
Key figures
- Total Debt
- 136765
- Debt Amount
- 1875000
- Cash Position
- 857489
- Interest Rate
- 10
- Maturity Date
- July 9, 2027
- Shares Outstanding
- 45112406
- Ga Expenses
- 2507383
- Rd Expenses
- 2338345
- Operating Expenses
- 4845728
- Derivative Liabilities
- 2396722
- Net Cash Used In Operations
- 2800000
Price after filing
Close on the filing date to close N calendar days later (from $0.03). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.